Western blot shows lysates of NCI‑N87 human gastric carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human Corneodesmosin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5725) ...read more
Corneodesmosin was detected in immersion fixed paraffin-embedded sections of human skin using Sheep Anti-Human Corneodesmosin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5725) at 1.7 µg/mL ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Corneodesmosin Antibody
differentiated keratinocyte S protein
Corneodesmosin, also known as CDSN and the S gene product, is a highly polymorphic secreted glycoprotein that plays an important structural role in the skin (1). It is expressed by differentiated keratinocytes in the corneal layer of the skin and is a major component of corneodesmosomes (2-4). It is also expressed in the inner root sheath of hair follicles (5, 6). Corneodesmosome has a high content of glycine, serine, and proline residues that promote its folding into a series of Gly-loop domains (2, 7). Corneodesmosin forms oligomers and associates homophilically to strengthen the adhesion between corneocytes (8, 9). Corneodesmosin-deficient mice exhibit a detachment of the corneal layer of the skin as well as hypotrichosis of the scalp and baldness (6, 10). Corneodesmosin is secreted by keratinocytes as a 52-56 kDa molecule which is then subjected to repeated sequential N- and C-terminal proteolysis (11). Species of 46, 43, 36, and 15 kDa are present in corneocytes (7, 11). Cleavage of the N-terminal Gly-loop diminishes Corneodesmosin’s ability to mediate adhesion, and this is a prerequisite for normal desquamation of the skin (8, 9). Reduced proteolysis of Corneodesmosin in psoriasis lesions is associated with the persistence of corneodesmosomes and scale retention (12). Premature truncation of Corneodesmosin is associated with hypotrichosis of the scalp (13).
Pierard, G.E. et al. (2000) Int. J. Mol. Med. 6:217.
Zhou, Y. and D.D. Chaplin (1993) Proc. Natl. Acad. Sci. USA 90:9470.
Haftek, M. et al. (1997) Br. J. Dermatol. 137:864.
Simon, M. et al. (1997) J. Biol. Chem. 272:31770.
Mils, V. et al. (1992) J. Histochem. Cytochem. 40:1329.
Matsumoto, M. et al. (2008) Proc. Natl. Acad. Sci. USA 105:6720.
Guerrin, M. et al. (1998) J. Biol. Chem. 273:22640.
Jonca, N. et al. (2002) J. Biol. Chem. 277:5024.
Caubet, C. et al. (2004) J. Invest. Dermatol. 122:747.
Leclerc, E.A. et al. (2009) J. Cell Sci. 122:2699.
Simon, M. et al. (2001) J. Biol. Chem. 276:20292.
Simon, M. et al. (2008) Br. J. Dermatol. 159:77.
Levy-Nissenbaum, E. et al. (2003) Nat. Genet. 34:151.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Corneodesmosin Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.